Guideline Recommended Practice Prescribing Beta Blocker therapy to patients with LV Systolic Dysfunction Use of 1 of the 3 beta blockers proven to reduce mortality is recommended for all stable patients with current or prior symptoms of heart failure and reduced LVEF. Unless contraindicated, patients with LV systolic dysfunction should be treated with one of the three following beta-blockers: *Prescribe may include prescription given to the patient for beta-blocker therapy at one or more visits in the measurement period OR patient already taking betablocker therapy as documented in current medication list SPECIAL NOTE: This measure is paired with performance measure "Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction". Beta-adrenergic receptor blockers play an important role in the management of cardiovascular disease, including hypertension, ischemic heart disease and chronic heart failure. They differ, though, in beta-selectivity, vasodilation properties, and other ancillary features. Recently, third generation, vasodilating, beta-blockers were introduced into practice. The vasodialtor effect of these three agents is obtained via the blockade of the alpha receptors. Oto, MD, FESC, FACC, FHRS*, *Professor of Cardiology, Department of Cardiology, Hacettepe University. However nebivolol shows a highly selective beta-1 blocking effects and confers an endothelium dependent vasodilatation via activation of L-arginin/NO pathway. Beta blocker treatment of patients with diastolic heart failure and arterial hypertension. Randomized trial to determine the effect of nebivolol on mortality and cardiovascusar hospital admission in elderly patients with heart failure (SENIORS). (25) The Beta-Blocker Evaluation of Survival Trial Investigators. Carvedilol: After oral administration, absorption is fast and reaches maximum plasma concentration within 1-2 hours. Long-term (3 months) effect of new b-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. A prospective, randomized, comparison of the long-term effects of atenolol vs nebivolol. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. (26) Anderson JL, Krause-Steinrauf H, Goldman S, et al for the Beta-blocker Evaluation of Survival Trial (BEST) Investigators. ß-blockers in heart failure: a comparison of a vasodilating ß-blocker with metoprolol. The plasma half-life is 7-10 hours, and should be given twice daily. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Failure of benefit and early hazard of bucindolol for class IV heart failure.
In patients with diabetes and heart failure, treatment with the beta-blocker metoprolol succinate CR/XL (controlled release/extended release) safely reduces the risk of hospitalization and mortality. Concern over lack of efficacy and potential adverse effects have prevented many doctors from prescribing beta-blockers for patients with diabetes and heart failure, lead author Dr. Deedwania of the University of California at San Francisco School of Medicine and colleagues note. As part of the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF), 985 diabetics and 3006 nondiabetics were randomized to metoprolol or placebo. The subjects, ages 40 to 80, with NYHA class II to IV heart failure, were followed for an average of 1 year. Active treatment reduced the risk of hospitalization for heart failure by 37% in the diabetic group (p = 0.0026) and by 35% in the nondiabetic group (p = 0.0002). For patients with severe heart failure, corresponding reductions were 53% and 44%. In the diabetic group, all-cause mortality risk was lowered 18% in the metoprolol CR/XL group. The aim of this study was to observe the efficacy and safety of Metoprolol (Met) plus Trimetazidine (Tri) in the treatment of Coronary Heart Failure (CHF). From January 2012 to January, 200 patients with coronary heart disease and heart failure who were treated at our hospital were selected as research subjects and randomly divided into a Control group (group C) and an Observation group (group O), with 100 patients in each group. The total efficacy rate in group O was 91.0%, higher than the 74.0% in group C and the difference was statistically significant (P A total of 200 CHF patients admitted in Beijing Aerospace General Hospital between January 2012 and January 2015 were selected as the study subjects. All the patients met the diagnostic criteria for ischemic heart disease issued by the World Health Organization (WHO) and mainly exhibited one or more of the following symptoms: dyspnea, fatigue, lower extremity edema, shortness of breath, pulmonary rales, pleural effusion, elevated jugular venous pressure, and peripheral edema. Patients with severe liver dysfunction, severe hypertension, severe arrhythmia, acute cerebrovascular diseases, acute pulmonary edema, cancer, acute infections, or psychiatric disorders were excluded . Eighty patients were classified in accordance with the New York Heart Association classification as follows: class I, 32 cases; class II, 25 cases; class III, 13 cases; and class IV, 10 cases. All the patients were randomly divided into groups C and O, with 100 patients in each group.
Coronary heart failure, Metoprolol, Safety, Trimetazidine. Introduction. Heart failure is a series of syndromes caused by multi-diseaseinduced myocardial dysfunction and cardio-blood transfusion dysfunction, and may be accompanied by various serious diseases. For heart failure, some clinicians use metoprolol tartrate, but it is best to stick with agents with proven outcomes in heart failure e.g. carvedilol, bisoprolol, metoprolol succinate Evidence level C; consensus.10. It has been suggested that patients can be switched from metoprolol succinate to an.